Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

As of this month, over 4,000 Americans are on the waiting list to receive a heart transplant. With failing hearts, these patients have no other options; heart tissue, unlike other parts of the body, is unable to heal itself once it is damaged. Fortunately, recent work by a group at Carnegie Mellon could one day lead to a world in which transplants are no longer necessary to repair damaged organs.

“We’ve been able to take MRI images of coronary arteries and 3-D images of embryonic hearts and 3-D bioprint them with unprecedented resolution and quality out of very like collagens, alginates and fibrins,” said Adam Feinberg, an associate professor of Materials Science and Engineering and Biomedical Engineering at Carnegie Mellon University. Feinberg leads the Regenerative Biomaterials and Therapeutics Group, and the group’s study was published in the October 23 issue of the journal Science Advances. A demonstration of the technology can be seen below.

“As excellently demonstrated by Professor Feinberg’s work in bioprinting, our CMU researchers continue to develop novel solutions like this for problems that can have a transformational effect on society,” said Jim Garrett, Dean of Carnegie Mellon’s College of Engineering. “We should expect to see 3-D bioprinting continue to grow as an important tool for a large number of medical applications.”

Read more

Treating the brain isn’t like the rest of the body. Your blood-brain barrier shields it; filtering the blood to ensure nothing untoward makes it through. This protection is normally a good thing, but it becomes a problem if you want to deliver therapeutic drugs through it. This method could be a solution.

Smuggling therapeutics

Many diseases like Parkinson’s and Alzheimer’s disease are extremely difficult to treat. Only very specific molecules can make it through the brain’s secure barrier, and most drugs don’t make the cut. This poses a challenge when you want to treat disease inside the brain, and so efforts have been focused on finding a way to overcome this. New research has now demonstrated a way of treating Parkinson’s disease with a surgical treatment that opens up a small route to bypass the barrier; essentially a smuggling hatch into your brain.

Read more

The much pursued fountain of youth can become a reality if humans agree to share their DNA information, according to Google Ventures’ CEO Bill Maris, who has warned that “we’re all going to die” earlier if we keep our genetic codes secret.

Maris, who aims to digitize DNA, stressed during a Wall Street Journal technology conference in California that our genomes “aren’t really secret,” urging those protective of their genetic information to loosen the reins a bit.

Noting that genetic material is constantly left lying around in public, Maris addressed those who remain nervous about the digitization of DNA. “What are you worried about?” he said on Tuesday, adding that a person could easily gather information by fishing a used cup out of the trash and taking it to a lab for analysis.

Read more

The $1.7 billion investment has finally opened its doors to the public, and the robots are ready to provide patients with a medical experience that’s truly revolutionary.

Hailed as the first fully digital hospital in North America, the Humber River Hospital in Toronto, CA finally opened its doors to the public on October 18. In addition to being equipped with the most advanced technologies, robots currently man several areas of the facility. This includes the radiology area where they facilitate the X-Ray procedure and the chemotherapy area where they mix, prepare, and monitor the drugs being administered to the patients. Before the drugs get to the patients, each package is checked and scanned thoroughly through an information management system to make sure that the patients get the correct treatment. These automated robots will also be assisting the health care staff by carrying and delivering medical supplies and food for patients.

Here’s a video of one of the automated robots in action:

Read more

Remember that paralyzed guy from Southern California who managed to walk on his own accord thanks to a revolutionary technique that bridged the gap in his severed spinal column with a wireless Bluetooth link? A team of doctors at Ohio’s Case Western Reserve University have reportedly accomplished the same feat with a patient’s arms.

The team described its initial findings at a meeting of the Society for Neuroscience in Chicago on Tuesday. The system works much like that of the earlier team at UC Irvine: a brain-control interface (BCI) reads the patient’s brain waves emanating from his motor cortex, converts them into actionable electrical signals and wirelessly transmits them to an actuator “sewn into” the patient’s arm. This actuator is comprised of 16 filament wires that generate electrical impulses, which cause various muscle groups to contract when stimulated. The patient thinks about moving his arm and it does so — well, sorta.

Read more

As long as they don’t enter the food supply.

First micropigs, now dogs: Scientists in China have used a gene-editing technique to produce the world’s first genetically engineered pooches. Although these two endeavors share scientific roots, with their production aimed at assisting medical research, unlike the teeny tiny pigs, the researchers behind this latest project are not intending to sell their customized animals as pets.

So it probably won’t come as a surprise that the dogs weren’t engineered to be cuter, fluffier or more pocket-sized: they had their DNA tweaked to make them more muscly. The first of many potential edits the team would like to carry out, this was done with the forces in mind.

With greater muscle mass, the dogs “are expected to have a stronger running ability, which is good for hunting, police (military) applications,” researcher Liangxue Lai from the Guangzhou Institutes of Biomedicine and Health told MIT Technology Review. Later on down the line, the scientists would like to manipulate the dog genome in order to mimic human diseases, which could better our understanding and treatment of certain conditions.

Read more

How cool is this!

Rendering of a virus used in the MIT experiments. The light-collecting centers, called chromophores, are in red, and chromophores that just absorbed a photon of light are glowing white. After the virus is modified to adjust the spacing between the chromophores, energy can jump from one set of chromophores to the next faster and more efficiently. (credit: the researchers and Lauren Alexa Kaye)

MIT engineers have achieved a significant efficiency boost in a light-harvesting system, using genetically engineered viruses to achieve higher efficiency in transporting energy from receptors to reaction centers where it can be harnessed, making use of the exotic effects of quantum mechanics. Emulating photosynthesis in nature, it could lead to inexpensive and efficient solar cells or light-driven catalysis,

This achievement in coupling quantum research and genetic manipulation, described this week in the journal Nature Materials, was the work of MIT professors Angela Belcher, an expert on engineering viruses to carry out energy-related tasks, and Seth Lloyd, an expert on quantum theory and its potential applications, and 15 collaborators at MIT and in Italy.

Read more

To whom it may concern,

Cryonics is a legitimate science-based endeavor that seeks to preserve human beings, especially the human brain, by the best technology available. Future technologies for resuscitation can be envisioned that involve molecular repair by nanomedicine, highly advanced computation, detailed control of cell growth, and tissue regeneration.

With a view toward these developments, there is a credible possibility that cryonics performed under the best conditions achievable today can preserve sufficient neurological information to permit eventual restoration of a person to full health.

Read more

Nature invented software billions of years before we did. “The origin of life is really the origin of software,” says Gregory Chaitin. Life requires what software does (it’s foundationally algorithmic).

1. “DNA is multibillion-year-old software,” says Chaitin (inventor of mathematical metabiology). We’re surrounded by software, but couldn’t see it until we had suitable thinking tools.

2. Alan Turing described modern software in 1936, inspiring John Von Neumann to connect software to biology. Before DNA was understood, Von Neumann saw that self-reproducing automata needed software. We now know DNA stores information; it’s a biochemical version of Turning’s software tape, but more generally: All that lives must process information. Biology’s basic building blocks are processes that make decisions.

Read more

Dr Michael Fossel comments on the recent Bioviva announcement of the first human gene therapy against aging.

The other day, a friend of mine, Liz Parrish, the CEO and founder of BioViva, made quite a splash when she injected herself with a viral vector containing genes for both telomerase and FST. Those in favor of what Liz did applaud her for her courage and her ability to move quickly and effectively in a landscape where red tape and regulatory concerns have – in the minds of some – impeded innovation and medical care. Those opposed to what Liz did have criticized her for moving too rapidly without sufficient concern for safety, ethics, or (from some critics) scientific rationale.

Many people have asked me to comment, both as an individual and as the founder of Telocyte. This occurs for two reasons. For one thing, I was the first person to ever advocate the use of telomerase as a clinical intervention, in discussions, in published journal articles, and in published books. My original JAMA articles (1997 and 1998), my first book on the topic (1996), and my textbook (2004) all clearly explained both the rational of and the implications for using telomerase as a therapeutic intervention to treat age-related disease. For another thing, Liz knew that our biotech firm, Telocyte, intends to do almost the same thing, but with a few crucial differences: we will only be using telomerase (hTERT) and we intend to pursue human trials that have FDA clearance, have full IRB agreement, and meet GMP (“Good Medical Production”) standards.

We cannot help but applaud Liz’s courage in using herself as a subject, a procedure with a long (and occasionally checkered) history in medical science. Using herself as the subject undercuts much of the ethical criticism that would be more pointed if she used other patients. Like many others, we also fully understand the urgent need for more effective therapeutic interventions: patients are not only suffering, but dying as we try to move ahead. In the case of Alzheimer’s disease, for example (our primary therapeutic target at Telocyte), there are NO currently effective therapies, a history of universal failure in human trials for experimental therapies, and an enormous population of patients who are currently losing their souls and their lives to this disease. A slow, measured approach to finding a cure is scarcely welcome in such a context.

Read more